MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.25% | -0.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.69% | 27.83% | |||
| Operating Income | -17.69% | -27.83% | |||
| Income Before Tax | -26.13% | -38.48% | |||
| Income Tax Expenses | 21.05% | -37.91% | |||
| Earnings from Continuing Operations | -26.12% | -38.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 16.13% | 35.12% | |||
| Net Income | -26.27% | -38.24% | |||
| EBIT | -17.69% | -27.83% | |||
| EBITDA | -17.90% | -27.28% | |||
| EPS Basic | -26.09% | -38.14% | |||
| Normalized Basic EPS | -26.21% | -38.48% | |||
| EPS Diluted | -26.09% | -38.14% | |||
| Normalized Diluted EPS | -26.21% | -38.48% | |||
| Average Basic Shares Outstanding | 0.14% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||